Rezum uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia.
 
Status In progress
Process MT
ID number 413

Provisional Schedule

Committee meeting: 1 15 November 2019
Draft guidance: 1 06 December 2019 - 08 January 2020
Committee meeting: 2 24 January 2020
Resolution 24 February 2020
Expected publication 06 April 2020

Project Team

Project lead Ying-ying Wang

Email enquiries

Stakeholders

External assessment group Newcastle Upon Tyne Hospitals
Manufacturers Boston Scientific
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Association for Perioperative Practice
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  British Association of Day Surgery
  Royal College of Anaesthetists
  Royal College of Surgeons of England
  The Association for Perioperative Practice
  The College of Operating Department Practitioners
  British Association of Urological Surgeons
Professional groups British Urological Group (BUG)
  PSA Prostate Cancer Support Association

Timeline

Key events during the development of the guidance:

Date Update
09 July 2019 Scope published
24 May 2019 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance